Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors

Immunobiology

Volumn 201, Issue 1, 1999, Pages 133-144

  Gruber, Andreas ^a,d   Berlit, Jan ^a   Speth, Cornelia ^a   Lass Flörl, Cornelia ^a   Kofler, Gabriele ^b   Nagl, Markus ^a   Zepelin, Margarete Borg Von ^c   Dierich, Manfred P ^a,b   Würzner, Reinhard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Fed Stt Inst Bacteriological S   (Austria)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRULENCE FACTOR;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; COLONY FORMATION; CROSS REACTION; DOSE RESPONSE; DRUG ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRULENCE;

EID: 0032851567     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(99)80052-7     Document Type: Article

References (34)

1. KLEIN, R. S., C. A. HARRIS, C. B. SMALL, B. MOLL, M. LESER, and G. H. FRIEDLAND. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 354.
2. WADE, J. C. 1993. Candidiasis - Pathogenesis, diagnosis and Treatment, Raven Press, New York, 85 pp.
3. BORG-VON ZEPELIN, M., and R. RÜCHEL. 1988. Expression of extracellular acid proteinase by proteolytic Candida spp. during experimental infection of oral mucosa. Infect. Immun. 56: 626.
4. WHITE, T. C., and N. AGABIAN. 1995. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J. Bacteriol. 177: 5215.
5. HUBE, B. 1996. Candida albicans secreted aspartyl proteases. Curr. Top. Med. Mycol. 7: 55.
6. BORG-VON ZEPELIN M., S. BEGGAH, K. BOGGIAN, D. SANGLARD, and M. MONOD. 1998. The expression of the secreted aspartyl proteinases SAP 4 to SAP 6 from Candida albicans in murin macrophages. Mol. Microbiol. 28: 543.
7. DE BERNARDIS, F., S. ARANCIA, L. MORELLI, B. HUBE, D. SANGLARD, W. SCHäFER, and A. CASSONE. 1999. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP 2, are virulence factors for Candida vaginitis. J. Infect. Dis. 179: 201.
8. KOHL, N. E., E. A. EMINI, W. A. SCHLEIF, et al. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85: 4686.
9. FLEXNER, C. 1998. HIV-Protease Inhibitors. N. Engl. J. Med. 338: 1281.
10. POWDERLY, W. G., A. LANDAY, and M. M. LEDERMAN. 1988. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 280: 72.
11. HOOD, S., A. BININGTON, J. EVANS, and D. DENNING. 1998. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 12: 447.
12. ZINGMAN, B. S. 1996. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334: 1674.
13. VALDEZ, H., B. M. GRIPSHOVER, R. A. SALATA, and M. M. LEDERMAN. 1998. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 12: 538.
14. HOEGL, L., E. THOMAGREBER, M. ROCKEN, and H. C. KORTING. 1998. HIV protease inhibitors influence the prevelence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses 41: 321.
15. CAUDA, R., E. TACCONELLI, M. TUMBARELLO, G. MORACE, F. DE BERNARDIS, A. TOROSANTUCCI, and A. CASSONE. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Acq. Immun. Def. Syndr. 21: 20.
16. SHAO, W., L. EVERITT, M. MANCHESTER, D. D. LOEB, C. A. HUTCHISON, and R. SWANSTROM. 1997. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. USA 94: 2243.
17. GRUBER, A. 1997. Einfluss des HIV-1 Proteinaseinhibitors Indinavir auf die Virulenz von C. albicans in vitro. In: Molekulares Mimikry zwischen HIV-1, Candida albicans und menschlichen Komplementkomponenten. PhD thesis, University of Kaiserslautern, Germany.
18. GRUBER, A., E. LUKASSER-VOGL, R. ZANGERLE, M. BORG-VON ZEPELIN, M. P. DIERICH, and R. WÜRZNER. 1999. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41: 227.
19. GRUBER, A., E. LUKASSER-VOGL, R. ZANGERLE, M. BORG-VON ZEPELIN, M. P. DIERICH, and R. WÜRZNER. 1998. Candida albicans: Attenuation of fungal virulence properties in vitro by an HIV-1 protease inhibitor. Immunobiol. 199: 647.
20. SAMMARANAYAKE, L. P., and P. HOMSTRUP. 1989. Oral candidiasis and human immunodeficiency virus infection. J. Oral Pathol. Med. 18: 554.
21. MACDONALD, F., and F. C. ODDS. 1980. Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. J. Med. Microbiol. 13: 423.
22. MOSSMANN, T. 1983. Rapid collorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods 65: 5563.
23. BJERKNES, R. 1984. Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans. J. Immunol. Methods 72: 229.
24. ABAD-ZAPATERO, C., R. GOLDMAN, S. W. MUCHMORE, et al. 1996. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci. 5: 640.
25. DORSEY, B. D., R. B. LEVIN, S. L. MCDANIEL, et al. 1994. L-735, 524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37: 3443.
26. SEELMEIER, S., H. SCHMIDT, V. TURK, and K. VON DER HELM. 1988. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85: 6612.
27. CASSONE, A., E. ADRIANI, E. TACCONELLI, R. CAUDA, and F. DE BERNARDIS. 1998. HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase. 12th World AIDS Conference (Geneva) 1998 Abstract 42358.
28. DIZ, P., A. OCAMPO, I. IGIESIAS, and I. OTERO. 1999. Lack of Ritonavir antifungal effect in vitro. Antimicrob. Agents Chemother. 43: 997.
29. DE BERNARDIS, F., P. CHIANI, M. CICCOZZI, G. PELLEGRINI, T. CEDDIA, G. D'OFFIZZI, I. QUINTI, P. A. SULLIVAN, and A. CASSONE. 1996. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect. Immun. 64: 466.
30. OLLERT, M. W., C. WENDE, M. GORLICH, C. G. MCMULLAN-VOGEL, M. BORG-VON ZEPELIN, C. W. VOGEL, and H. C. KORTING. 1995. Increased expression of Candida albicans secretory proteinase, a putative virulence factor in isolates from human immunodeficiency virus-positive patients. J. Clin. Microbiol. 33: 2543.
31. WÜRZNER, R., A. GRUBER, H. STOIBER, M. SPRUTH, Y. H. CHEN, E. LUKASSER-VOGL, M. SCHWENDINGER, and M. P. DIERICH. 1997. Human immunodeficiency virus type 1 gp41 binds to Candida albicans via complement C3-like regions. J. Infect. Dis. 176: 492.
32. GRUBER, A., E. LUKASSER-VOGL, M. BORG-VON ZEPELIN, M. P. DIERICH, and R. WÜRZNER. 1998. Human immunodeficiency virus type 1 gp160/gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J. Infect. Dis. 177: 1057.
33. BORG-VON ZEPELIN, M., and T. WAGNER. 1995. Fluorescence assay for the detection of adherent Candida yeasts to target cells in microtest plates. Mycoses 38: 339.
34. BORG-VON ZEPELIN, M., I. MEYER, D. SANGLARD, and M. MONOD. 1999. Inhibition of secreted aspartic Candida proteinases and reduction of adherence of Candida strains by different HIV proteinase inhibitors. Mycoses 42: 127.